Episode Details

Midlife Mayhem: CBL-514, the Injectable That Could Change Cellulite and Stubborn Fat

Is an injection, pill or potion coming for everything? This week Joanne looks at CBL-514, an experimental injectable aimed at stubborn fat and cellulite, and shows how to read a breakthrough headline without getting swept away.

🎧 In This Episode

Cellulite and stubborn fat are the two things midlife women ask about most. CBL-514 is an experimental injectable developed for both. It isn’t approved anywhere and can’t be bought, but it points to where this whole field is heading, and it makes a great case study in reading the headlines critically.

🔬 What Is CBL-514?

• Developed by Taiwanese company Calaway Biopharmaceuticals
• A small molecule injection (not a peptide)
• Designed for non-surgical, localized fat reduction and moderate to severe cellulite
• Still in clinical trials, not approved anywhere

💡 Why It’s Different: Fewer Fat Cells, Not Just Smaller Ones

• Diet, training and even GLP-1 medications shrink the size of the fat cells you already have, like letting the water out of a balloon. The cell is still there, which is why weight regain is so common.
• CBL-514 is proposed to induce apoptosis (programmed cell death) in fat cells, so there are fewer fat cells in a targeted area.
• Think of it as an injectable liposuction.
• If the fat cell is gone, it can’t refill.

📊 What the Data Shows So Far

• Early phase 2a study: abdominal fat volume dropped about 25%, roughly 120 ml (about half a cup)
• Reported cellulite results: roughly 95% of women with moderate to severe cellulite saw significant improvement

Reading the Headline: Key Caveats

1. The results come from the company’s own announcement. That doesn’t make them false, but companies share their most flattering numbers.
2. The study was open label. Participants knew what they were being treated with, and in aesthetics, expectation matters. Placebo-controlled data is the goal.
3. 120 ml is meaningful, but the real question is what it looks like on a real body in the mirror.

🧪 What’s Next: The Trials

• Phase 3 trial, “Supreme 01”: randomized, double-blind and placebo-controlled; started September 2026 and currently recruiting
• A second pivotal trial has been cleared by the FDA
• Results from both are expected sometime in 2027
• Trials use MRI to measure fat volume alongside patient-reported scales
• After that comes regulatory review, so the product is likely a long way off

🧬 Why Cellulite Is So Hard to Treat

• It isn’t simply too much fat. It’s largely structural.
• Bands of connective tissue anchor the skin to a deeper layer, and fat pushes up between the bands, creating dimples.
• That’s why lean, fit women can have cellulite and some heavier women have none.
• Hormones, genetics and skin thickness all play a role, and it often worsens after 30 and through menopause as skin thins and collagen declines.
• Past treatments have had mixed results: an injectable called Qwo (collagenase) is no longer sold in the US, and devices can help modestly but need a lot of maintenance. Joanne also trained in Endermologie and says it can help.

💉 The Weight-Loss Medication Angle

• Many women on weight-loss medications worry about muscle loss and rapid regain after stopping.
• Calaway presented animal data at the American Diabetes Association meeting in 2026, looking at CBL-514 combined with tirzepatide. The company says it may help reduce weight regain after stopping treatment and improve metabolic health.
• Human trials of the combination are planned to begin very soon.
• As Joanne notes, animal studies aren’t small humans, so the human results are t